SU5402 is primarily used in research settings as a potent inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. It is widely applied in studies focusing on angiogenesis, tumor growth, and cellular signaling pathways. Researchers utilize SU5402 to investigate the role of FGFR and VEGFR in various biological processes, including embryonic development, wound healing, and cancer progression. By inhibiting these receptors, SU5402 helps elucidate their functions and potential as therapeutic targets. Additionally, it is employed in in vitro and in vivo experiments to explore the effects of blocking these signaling pathways in disease models, particularly in cancers where FGFR and VEGFR are overexpressed or dysregulated.